 |
 |
|
|
Edgemont Capital Partners®
is a specialty advisory firm dedicated to providing
the highest quality strategic advisory and capital raising services to
emerging through mid-sized healthcare companies.
We are senior professionals with extensive healthcare investment banking
experience at leading Wall Street firms. Combined, we've completed over
70 healthcare industry transactions,
representing more than $30 billion in total value for healthcare companies
ranging from start-ups to large multinationals. We are a registered Broker
/ Dealer with FINRA and we have raised over $2 billion in capital for
healthcare companies over our careers.
We are committed to building a premier healthcare merchant banking firm.
Over the past 15 years, more than 50 well-known healthcare investment
banking/advisory firms were acquired, merged, consolidated or have disappeared
altogether (click here to see our healthcare
investment banking industry timeline).
As a result, we believe that many emerging, growing and established mid-sized
healthcare companies encounter difficulty attracting quality banking advisors
with senior level commitment from experienced professionals. We are focused
entirely on serving these companies.
Edgemont Capital Partners®
services include investment banking, corporate financial analysis and consultation
for healthcare companies in the areas of business acquisitions and mergers,
pharmaceutical licensing, private placements of debt and equity, financial
valuations of business assets and fairness opinions.
Our merger and acquisitions services:
• Exclusive sale assignments
• Acquisitions, divestitures (and fairness opinions in relation thereto)
• Corporate partnering
• Restructuring
• Leveraged and management buyouts
• Financial advisory
• Financial valuations
Our pharmaceutical products licensing services:
• Acquisition and divestiture of pharmaceutical products
• Development and marketing licensing
• Financial valuations
Our financing services:
• Private placements of equity
• Private placements of debt
• Fairness opinions
• Financial valuations
|
|
|
|
|
